Vanguard Fiduciary Trust
CBIO

Vanguard Fiduciary Trust’s Crescent Biopharma CBIO Stock Holding History

Vanguard Fiduciary Trust’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.35M Buy
75,225
+25,802
+52% +$504K ﹤0.01% 2885
2026
Q1 		$908K Buy
+49,423
New +$567K ﹤0.01% 2965

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust's CBIO Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Crescent Biopharma (CBIO) stake by 52% in Q2 2026, buying an estimated $504K and bringing the position to 75,225 shares worth $1.35M. The position accounts for ﹤0.01% of the portfolio, ranked #2885.

Vanguard Fiduciary Trust first reported a position in CBIO in Q1 2026 and has held it in 2 quarters since. 82 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • Vanguard Fiduciary Trust held 75,225 shares of Crescent Biopharma worth $1.35M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 25,802 Crescent Biopharma shares in Q2 2026, an estimated $504K.
  • Crescent Biopharma made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #2885 holding.
  • Vanguard Fiduciary Trust first reported a position in Crescent Biopharma in Q1 2026 and has held it in 2 quarters since.
  • 82 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.